Galunisertib (LY2157299)

For research use only.

Catalog No.S2230

122 publications

Galunisertib (LY2157299) Chemical Structure

CAS No. 700874-72-2

Galunisertib (LY2157299) is a potent TGFβ receptor I (TβRI) inhibitor with IC50 of 56 nM in a cell-free assay. Phase 2/3.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 272 In stock
USD 170 In stock
USD 270 In stock
USD 770 In stock
USD 1990 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Galunisertib (LY2157299) has been cited by 122 publications

Purity & Quality Control

Choose Selective TGF-beta/Smad Inhibitors

Biological Activity

Description Galunisertib (LY2157299) is a potent TGFβ receptor I (TβRI) inhibitor with IC50 of 56 nM in a cell-free assay. Phase 2/3.
TβRI [1]
(Cell-free assay)
56 nM
In vitro

LY2157299 potently inhibits the TGFβ receptor signaling. LY2157299 abolishes the TGFβ induced Smad2 phosphorylation in HUVEC cells. LY2157299 also shows dose dependent potentiation of VEGF or bFGF induced cell proliferation in HUVEC. LY2157299 also promotes VEGF induced HUVEC cell migration. LY2157299 potentiates angiogenesis in the in vitro VEGF-stimulated cord formation assay. [2] LY2157299 inhibits TGF-β-mediated SMAD2 activation and hematopoietic suppression in primary hematopoietic stem cells in a dose-dependent manner. LY2157199 treatment stimulates hematopoiesis from primary MDS bone marrow specimens. [3] In human glioblastoma (GBM) cells, LY2157299 treatment blocks signaling through the heteromeric TGFβ receptor complex to reduce levels of active, phosphorylated SMAD. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Panc-1 MmqwSpVv[3Srb36gRZN{[Xl? NUn2cYtPOTBizszN NW[2V2RWPDhiaB?= NXnJZnV4TE2VTx?= M2KyXpN1cW23bHH0[ZMhfGinIHPlcIwhcW64YYPpc44hcW62bzD0bIUh[2:ubHHn[Y4h\2WuIHHu[EB1cGViTXH0dolo\WxvY3;heIVlKGOxbHzh[4VvKGenbB?= M2frelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{iwPFIyLz5{NEe4NFgzOTxxYU6=
Sf9 NGriUnNHfW6ldHnvckBie3OjeR?= MmOzTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCJU2St[pV{\WRiQVzLOUBmgHC{ZYPz[YQhcW5iU3[5JIlve2WldDDj[YxteyC3c3nu[{Bk[XOnaX6gZZMhe3Wkc4TyZZRmKGK7IIDyc5BzcWW2YYL5JJJi\GmxaYPveI9xcWNicILveIVqdiCtaX7hd4Uh[XO|YYmsJGlEPTBiPTCwMlA3QTRizszNMi=> MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR6M{G5PEc,OjZ2OEOxPVg9N2F-
Sf9 Ml\VSpVv[3Srb36gZZN{[Xl? NEjidmdKdmirYnn0bY9vKG:oIHj1cYFvKEGOS{Wg[ZhxemW|c3XkJIlvKFOoOTDpcpNm[3RiY3XscJMhfXOrbnegZ4F{\WmwIHHzJJN2[nO2cnH0[UBqdiCycnXz[Y5k\SCxZjDb[4FudWFvM{PQYWFVWCxiSVO1NEA:KDBwMEWxJO69VS5? MlP0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzM{W2PFUoRjJ6MUO1Olg2RC:jPh?=
Sf9 NVWwPI1PTnWwY4Tpc44h[XO|YYm= MYKxJIhz MkL6TY5pcWKrdHnvckBw\iCqdX3hckBJcXNvdHHn[4VlKFSJRnLleIFTOSCWMkC0SEBufXSjboSg[ZhxemW|c3XkJIlvKFOoOTDpcpNm[3RiY3XscJMh[W[2ZYKgNUBpeiCkeTDIWHJHKGG|c3H5MEBKSzVyIE2gNE4xODRzIN88UU4> MnXEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2MkKzN|IoRjJ7NEKyN|MzRC:jPh?=
B16 NE[2SVRCdnSrdIXtc5Ih[XO|YYm= NEftXIs4PSCvZz;r[y=> M3SzUmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFKxOkBk\WyuczDpckBud3W|ZTDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIIT1cY9zKGe{b4f0bEBifCB5NTDt[{9s\yxicH:gZollKHKnbHH0bZZmKHSxII\lbIlkdGVvdILlZZRm\CClb370do9t MkTNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OE[1PFUoRjJ2N{i2OVg2RC:jPh?=
B16 M3nlbGFvfGm2dX3vdkBie3OjeR?= NXvk[IZLPzVibXevb4c> M3LJWmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFKxOkBk\WyuczDpckBud3W|ZTDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjD0eY1weiC4b3z1cYUh[XRiN{WgcYcwc2duIIDvJIJq\CC{ZXzheIl3\SC2bzD2[Yhq[2ynLYTy[YF1\WRiY3;ueJJwdA>? MonHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OE[1PFUoRjJ2N{i2OVg2RC:jPh?=
B16 NF\VWlZCdnSrdIXtc5Ih[XO|YYm= M3LTb|c2KG2pL3vn MXTBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEMU[gZ4VtdHNiaX6gcY92e2ViYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCueX3wbEBvd2SnIH3leIF{fGG|aYOgZZQhPzVibXevb4ctKHCxIHLp[EBz\WyjdHn2[UB1dyC4ZXjpZ4xmNXS{ZXH0[YQh[2:wdILvcC=> NVzhclByRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFY2QDVpPkK0O|g3PTh3PD;hQi=>

... Click to View More Cell Line Experimental Data

Methods Test Index PMID
Western blot
TGF-βR1 / p-ERK; 

PubMed: 30881035     

Western blot was performed to analyze the expression level of TGF-βR1, p-smad2 and p-ERK1/2. VECTOR, cells transduced with VECTOR lentivirus; VECTOR+ LY2157299, cells transduced with VECTOR lentivirus and treated with LY2157299; USP4, cells transduced with USP4 lentivirus; USP4+ LY2157299, cells transduced with USP4 lentivirus and treated with LY2157299.

Periostin / Fibronectin / Snail / Twist / pSmad2 / pERK / pAkt / pFAK; 

PubMed: 29774119     

U-87 MG cells were serum-starved for 24 h, then incubated in serum-free medium containing (or lacking) 10 μM Galunisertib (LY2157299) and 10 ng/mL of TGF-β for 48 h. Cells were lysed and expression levels of EMT markers periostin, fibronectin, Snail and twist, or the phosphorylation status of Smad2, Erk, Akt and Fak proteins were monitored by immunoblotting.

30881035 29774119
Growth inhibition assay
Cell viability; 

PubMed: 28873435     

Primary cell cultures were treated with LY2157299. MTS was performed at 72 hrs. TGF-ΒR1 inhibition by LY2157299 did not influence cell viability in any type of primary cell culture. 


PubMed: 29467918     

KPC-M09 cells were treated with control, TGFβ or TGFβ plus galunisertib (2 μM or 10 μM). Bright field images are shown in the top panel and were imaged at 20X. The bottom panel shows fluorescent IHC using anti-E-cadherin (red) as well as DAPI (blue) as a counter stain. Cells were imaged at 40X.

In vivo Although anti-tumor activity has been observed in several pre-clinical models, LY2157299 fails to show significant in vivo angiogenic effects in the 4T1, Colo205, or A549 xenograft models. [2] Administration of LY2157299 ameliorates anemia in a TGF-β overexpressing transgenic mouse model of bone marrow failure. [3] Oral administration of LY2157299 at 75 mg/kg/day displays significant antitumor activity against both Calu6 and MX1 xenografts in mice. [5] In vivo, LY2157299 induces angiogenesis and enhances VEGF and basic-fibroblast-growth-factor-induced angiogenesis in a Matrigel-plug assay, whereas adding an alpha5-integrin-neutralizing antibody to the Matrigel selectively inhibits this enhanced response. [6]


Animal Research:[5]
- Collapse
  • Animal Models: Nude mice implanted subcutaneously with Calu6 or MX1 cells
  • Dosages: 75 mg/kg/day
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 74 mg/mL (200.31 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
For best results, use promptly after mixing.

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 369.42


CAS No. 700874-72-2
Storage powder
in solvent
Synonyms N/A
Smiles CC1=NC(=CC=C1)C2=NN3CCCC3=C2C4=C5C=C(C=CC5=NC=C4)C(=O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03470350 Withdrawn Drug: Galunisertib Colorectal Cancer Metastatic The Netherlands Cancer Institute|Vall d''Hebron Institute of Oncology|Agendia|European Organisation for Research and Treatment of Cancer - EORTC|Azienda Ospedaliera Niguarda Cà Granda|Fundación para la Investigación del Hospital Clínico de Valencia|University of Campania Luigi Vanvitelli|University of Turin Italy|Eli Lilly and Company|Catalan Institute of Health|Universitaire Ziekenhuizen Leuven August 24 2018 Phase 1|Phase 2
NCT02734160 Completed Drug: Galunisertib|Drug: Durvalumab Metastatic Pancreatic Cancer Eli Lilly and Company|AstraZeneca June 15 2016 Phase 1
NCT02452008 Recruiting Drug: Enzalutamide|Drug: LY2157299 Prostate Cancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Eli Lilly and Company May 3 2016 Phase 2
NCT02752919 Completed Drug: Galunisertib Healthy Eli Lilly and Company April 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

TGF-beta/Smad Signaling Pathway Map

TGF-beta/Smad Inhibitors with Unique Features

Related TGF-beta/Smad Products

Tags: buy Galunisertib|Galunisertib ic50|Galunisertib price|Galunisertib cost|Galunisertib solubility dmso|Galunisertib purchase|Galunisertib manufacturer|Galunisertib research buy|Galunisertib order|Galunisertib mouse|Galunisertib chemical structure|Galunisertib mw|Galunisertib molecular weight|Galunisertib datasheet|Galunisertib supplier|Galunisertib in vitro|Galunisertib cell line|Galunisertib concentration|Galunisertib nmr|Galunisertib in vivo|Galunisertib clinical trial|Galunisertib inhibitor|Galunisertib TGF-beta/Smad inhibitor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID